阿卡波糖联合甘精胰岛素对2型糖尿病患者胰岛功能、血脂水平的影响及安全性

Effects of Acarbose Combined with Insulin Glargine on Pancreatic Islet Function and Blood Lipid Levels in Patients with Type 2 Diabetes Mellitus and Their Safety

目的观察阿卡波糖联合甘精胰岛素对2型糖尿病患者胰岛功能、血脂水平的影响及安全性。方法选取2018年1月—2020年12月就诊的102例2型糖尿病,根据治疗方式不同分为对照组48例和研究组54例,对照组给予阿卡波糖联合普通胰岛素治疗,研究组给予阿卡波糖联合甘精胰岛素治疗。比较两组治疗前后胰岛功能[稳态模型胰岛素抵抗指数(HOMA-IR)、胰岛素分泌指数(HOMA-β)]、血糖[空腹血糖(FPG)、餐后2 h血糖(2 h PG)及糖化血红蛋白(HbA1c)]、血脂[总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)]水平,并观察不良反应发生情况。结果治疗后,两组FPG、2 h PG、HbA1c、TC、TG、LDL-C及HOMA-IR水平均较治疗前降低,HDL-C及HOMA-β水平均较治疗前升高,且研究组上述指标降低或升高程度较对照组更为明显(P<0.05)。两组不良反应总发生率比较差异无统计学意义(P>0.05)。结论阿卡波糖联合甘精胰岛素治疗能够有效控制2型糖尿病患者的血糖,并改善血脂水平及胰岛功能,且联合用药后并未增加不良反应,具有一定安全性。

Objective To observe effects of Acarbose combined with Insulin Glargine on pancreatic islet function and blood lipid level in patients with type 2 diabetes mellitus(T2 DM)and their safety.Methods A total of 102 patients with T2 DM who had seen a doctor between January 2018 and December 2020 were selected and divided into control group(n=48)and research group(n=54)according to different therapeutic methods.Control group was treated with Acarbose combined with regular Insulin,while research group was treated with Acarbose combined with Insulin Glargine therapy.The islet function indexes[homeostasis model of assessment-insulin resistance(HOMA-IR),insulin secretion index(HOMA-β)],blood glucose indexes[fasting plasma glucose(FPG),2 h postprandial blood glucose(2 h PG)and glycated hemoglobin(HbA1 c)],blood lipids indexes[total cholesterol(TC),triacylglycerol(TG),low density lipoprotein cholesterol(LDL-C),high density lipoprotein cholesterol(HDL-C)]were compared before and after treatment,and incidence rates of adverse reactions were observed in two groups.Results After treatment,levels of FPG,2 h PG,HbA1 c,TC,TG,LDL-C and HOMA-IR were significantly lower,while levels of HDL-C and Homa-βwere significantly higher than those before treatment in two groups;the decreased or increased degrees of the above indexes in research group was more obvious than those in control group(P<0.05).There was no significant difference in the total incidence rate of adverse reactions between two groups(P>0.05).Conclusion Acarbose combined with Insulin Glargine therapy may effectively control blood sugar and improve blood lipid levels and islet function in treatment of patients with T2 DM.In addition,their combined application does not increase adverse reactions with good safety.